Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lifted its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 382.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 187,974 shares of the company's stock after acquiring an additional 149,000 shares during the period. Ensign Peak Advisors Inc owned approximately 0.20% of Scholar Rock worth $8,124,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its position in Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after purchasing an additional 269 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares during the last quarter. Amalgamated Bank grew its holdings in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after buying an additional 620 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after buying an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $42.67.

Insider Buying and Selling

In other news, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares in the company, valued at $4,154,541.60. This represents a 38.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jay T. Backstrom sold 18,372 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $676,640.76. Following the completion of the sale, the chief executive officer now owns 311,991 shares in the company, valued at $11,490,628.53. This represents a 5.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock valued at $9,220,236 over the last quarter. Company insiders own 13.30% of the company's stock.

Scholar Rock Stock Performance

Shares of SRRK stock traded down $0.28 during midday trading on Friday, hitting $30.55. The company had a trading volume of 1,075,653 shares, compared to its average volume of 1,273,907. The company's 50 day simple moving average is $31.19 and its 200 day simple moving average is $35.87. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). Research analysts anticipate that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.